According to a new
market report published by Transparency Market Research “Albumin
(Excipient) Market - Global Industry Analysis, Size, Share, Volume,
Growth, Trends and Forecast, 2014 - 2020,” the global albumin
excipient market was valued at USD 704.9 million in 2013 and is
expected to grow at a CAGR of 2.3% from 2014 to 2020, to reach an
estimated value of USD 828.2 million by 2020.
Selection of
appropriate excipients is very important during the development of
drug formulations and vaccines. A suitable excipient helps stabilize
and protect an active pharmaceutical ingredient (API) in the
formulation against degradation, oxidation or aggregation that the
API could undergo during manufacturing, transport and storage. As an
excipient, albumin has wide applications in drug formulation, drug
delivery, vaccine manufacturing and as a component of media for the
production of vaccines. Manufacturers are increasingly considering
innovative ways to reduce contamination risks of finished products
due to the recent incidents of animal virus contamination of
biopharmaceutical products. Manufacturers must adhere to strict
regulations on the standards and also provide detailed information on
the country of origin (BSE free), the types of tissue used and
details of the manufacturing process during the compliance and
approval procedure.
The global albumin
market is analyzed by albumin type, applications and geography. On
the basis of type, the market is segmented into human serum albumin,
bovine serum albumin and recombinant albumin. Human serum albumin was
the largest segment and was valued at USD 476.7 million in 2013. The
segment is expected to reach USD 557.0 million in 2020, growing at a
CAGR of 2.2% during the forecast period between 2014 and 2020. Bovine
serum albumin is used in the production of vaccines such as MMR II,
Varivax, Zostavax and RotaTeq in ranges of less than 1 ppm. Extensive
research to explore new ways is underway to increase virus yield and
quality in manufacturing. Recently, end-user preference has been
observed to have shifted towards recombinant human albumin (rAlbumin)
used in multiple applications such as in nano formulation and drug
carrier over specific therapeutic modalities. Advances in yeast-based
protein expression and the successful scale-up have led to the
development of an industrial-scale manufacturing process that can
produce a highly pure, animal-free rAlbumin suitable for use as an
excipient in biotherapeutics.
abumin-market
Primary applications
of albumin include drug formulation and drug delivery, vaccines, and
component of media. The drug formulation and drug delivery segment is
expected to reach USD 395.9 million in 2020. Expansion of the role of
albumin in drug delivery has widened the field of nanotechnology as
well. For instance, Abraxis BioScience has applied nanotechnology to
human serum albumin (HSA) with its nanoparticle albumin-bound, known
as ‘NAB’ technology platform. This approach combines HSA with an
API for delivering protein drugs.
Geographically,
North America continues to dominate the market due to high demand for
albumin in drug formulations, and research and development
activities. The albumin market in the region was valued at USD 253.8
million in 2013. The current focus of the research community in most
of the academic institutions and industry is to use albumin as a
carrier for micro- and nanoparticles for sustained-release injectable
drugs. Paclitaxel nano-particulate formulation containing albumin as
a carrier was approved by the U.S. FDA in September 2013. Countries
such as China, India and Australia exhibit significant growth
prospects in terms of rapid increase in the research collaboration
between industry and research institutions. GlaxoSmithKline
Pharmaceuticals Limited (GSK) is funding around USD 4 million per
year to initiate research and development program with the leading
research institutions in Asia Pacific for the development of
potential therapeutics.
Some of the major
companies operating in the global albumin market are CSL Behring,
HiMedia, InVitria, Mitsubishi Tanabe Pharma, Octapharma AG, Novozymes
A/S, Raybiotech, Inc., Sigma-Aldrich Corporation, Thermo Fischer
Scientific, Inc. and MedxBio Pte. Ltd. Pharmaceutical companies and
research institutes obtain the desired albumin excipient grade from
the market players for their development activities. The key players
in the global albumin market improve their distribution network by
entering into strategic alliances and distributorship agreements. For
instance, InVitria partnered with Thermo Fischer Scientific and
Sigma-Aldrich in order to provide its customers with product support
best tailored to meet their needs. InVitria has distributors across
the world including North America, Europe, Asia and Australia.
Browse the full
Albumin (Excipient) Market (Types: Human Serum Albumin, Bovine Serum
Albumin and Recombinant Albumin; Applications: Drug Formulation and
Drug Delivery, Vaccines, and Component of Media) - Global Industry
Analysis, Size, Share, Volume, Growth, Trends and Forecast, 2014 -
2020 report at
http://www.transparencymarketresearch.com/albumin-market.html
The global albumin
market is segmented as follows:
Albumin Market
Revenue (USD Million), by Type
Human Serum Albumin
Bovine Serum Albumin
Recombinant Albumin
Albumin Market
Revenue (USD Million) and Volume (kg), by Application
Drug Formulation and
Drug Delivery
Vaccines
Component of Medium
Albumin Market
Revenue (USD Million) and Volume (kg), by Geography
North America
Europe
Asia Pacific
Rest of the World
Request a Brochure
of this Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=3984
About Us
Transparency Market
Research is a global market intelligence company, providing global
business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers. Our experienced team of
Analysts, Researchers, and Consultants, use proprietary data sources
and various tools and techniques to gather, and analyze information.
Our data repository
is continuously updated and revised by a team of research experts, so
that it always reflects the latest trends and information. With a
broad research and analysis capability, Transparency Market Research
employs rigorous primary and secondary research techniques in
developing distinctive data sets and research material for business
reports.
Contact
Mr. Nachiket Ghumare
90 State Street,
Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll
Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
http://www.transparencymarketresearch.com/
No comments:
Post a Comment